Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers

British Journal of Clinical Pharmacology

Volumn 46, Issue 4, 1998, Pages 383-393

  Bellissant, Eric ^a,b   Giudicelli, Jean François ^a  

^a BICÊTRE HOSPITAL   (France)

^b Faculté de Médecine   (France)

Author keywords

Concentration effect relationship; Effect compartment; Haemodynamics; Healthy Volunteers; PK PD modeling; Sigmoid model; Zabicipril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ZABICIPRIL; ZABICIPRILAT;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMORAL ARTERY; HEMODYNAMICS; HUMAN; MALE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PRESSURE; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMORAL ARTERY; HUMANS; MALE; MODELS, BIOLOGICAL; PLACEBOS; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE;

EID: 0031664057     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00786.x     Document Type: Article

References (23)

1. Kroboth PD, Schmith VD, Smith RB. Pharmacodynaimc modelling. Application to new drug development. Clin Pharmacokinet 1991; 20: 91-98.
2. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51: 465-473.
3. Thuillez C, Leroy JP, Loueslati H, Bellissant E, Giudiccelli JF. Débits cardiaque et régionaux non invasifs chez le volontaire sain. Intérêt prédictif. Arch Mal Coeur 1989; 82: 1275-1279.
4. Meredith PA, Elliott HL, Donnelly R, Reid JL. Dose-response clarification in early drug development. J Hypertension 1991; 9(Suppl. 6): S356-S357.
5. Bellissant E, Thuillez C, Pussard E, Giudicelli JF. Systemic and regional hemodynamic effects of zabicipril in healthy volunteers. Clin Pharmacol Ther 1992; 51: 308-319.
6. Safar ME, Peronneau PA, Levenson JA, Toto-Moukouo JA, Simon AC. Pulsed Doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. Circulation 1981; 63: 393-400.
7. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20: 1637-1648.
8. Bellissant E, Chau NP, Giudicelli JF. A computer program tor kinetic-dynamic modeling in non steady-state experiments (abstract). Clin Pharmacol Ther 1996; 59: 147.
9. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
10. Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86-93.
11. Fuseau E, Sheiner LB. Simultaneous modeling of phannacokinetics and pharmacodynamics with a nonparametric pharrnacodynamic model. Clin Pharmacol Ther 1984; 35: 733-741.
12. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes. The art of scientific computing. Cambridge: Cambridge University Press, 1986.
13. Berman M. The formulation and testing of models. Ann NY Acad Sci 1963; 108: 182-194.
14. Bellissant E, Chau NP, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. J Cardiovasc Pharmacol 1996; 28: 470-478.
15. Bellissant E, Chau NP, Thuillez C, Gerbeau C, Richard C, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. J Cardiovasc Pharmacol 1997; 30: 253-260.
16. Bührer M, Maitre PO, Crevoisier C, Stanski DR. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990; 48: 555-567.
17. Patat A, Le Coz F, Dubruc C, et al. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoainme oxidase inhibitor, at steady state in healthy volunteers. J Clin Pharmacol 1996; 36: 216-229.
18. MacDonald NJ, Hughes DM, Lees KR, Reid JL. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man. Br J Clin Pharmacol 1990; 30: 107-113.
19. Kelman AW, Reid JL, Millar JA. Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol 1983; 15: 506-507.
20. Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL. Pharmacodynamics and population pharmacokinctics of enalapril and lisinopril. Int J Clin Pharm Res 1985; 6: 419-427.
21. Witte PU, Irmisch R, Hajdu P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects, Eur J Clin Pharmacol 1984; 27: 577-581.
22. Lees KR, Kelman AW, Reid JL. Effect of repeated dosing on concentration-effect relationships with the angiotensin converting enzyme inhibitor, perindopril. Br J Clin Pharmacol 1986; 22: 234P.
23. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol 1987; 9: 32-38.